The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...

Pfizer (PFE) stock is in focus as the firm with Astellas (ALPMF) post a Phase 3 trial win for Padcev cancer drug when used ...

Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...

Merck MRK is going to face a major patent cliff, as its blockbuster PD-L1 therapy Keytruda is nearing loss of exclusivity (LOE) in 2028. The company’s biggest revenue driver, Keytruda, is approved for ...

For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds A large clinical trial shows that for many patients with the most common type of lung cancer, ...